Nitronal 1mg/ml solution for infusion

Summary of Product Characteristics Updated 31-Oct-2023 | Beaumont Pharma Ltd

1. Name of the medicinal product

Nitronal® 1 mg/ml solution for infusion

2. Qualitative and quantitative composition

Glyceryl trinitrate 1 mg/ml.

5 ml ampoule contains 5 mg Glyceryl trinitrate

10 ml ampoule contains 10 mg Glyceryl trinitrate

25 ml ampoule contains 25 mg Glyceryl trinitrate

50 ml vial contains 50 mg Glyceryl trinitrate

Excipient(s) with known effect:

Glucose Monohydrate

For the full list of excipients, see section 6.1

3. Pharmaceutical form

Solution for infusion.

A clear colourless solution practically free from particles

4. Clinical particulars
4.1 Therapeutic indications

1. Unresponsive congestive heart failure, including that secondary to acute myocardial infarction.

2. Refractory unstable angina pectoris and coronary insufficiency, including Prinzmetal's angina.

3. Control of hypertensive episodes and / or myocardial ischaemia during and after cardiac surgery. For the induction of controlled hypotension for surgery.

4.2 Posology and method of administration

For intravenous use. Nitronal® should be administered by means of a micro-drip set infusion pump or similar device which permits maintenance of constant infusion rate.

Adults and the elderly - the dose should be titrated against the individual clinical response. Hypotension and syncope can be a problem with use of nitrates in the elderly. Lower initial doses are recommended.

1. Unresponsive congestive heart failure. The normal dose range is 10-100 micrograms / minute administered as a continuous intravenous infusion with frequent monitoring of blood pressure and heart rate. The infusion should be started at the lower rate and increased cautiously until the desired clinical response is achieved. Other haemodynamic measurements are extremely important in monitoring response to the drug: These may include pulmonary capillary wedge pressure, cardiac output and precordial electrocardiogram depending on the clinical picture.

2. Refractory unstable angina pectoris. An initial infusion rate of 10-15 micrograms / minute is recommended; this may be increased cautiously in increments of 5-10 micrograms until either relief of angina is achieved, headache prevents further increase in dose, or the mean arterial pressure falls by more than 20 mm Hg.

3. Use in surgery. An initial infusion rate of 25 micrograms / minute is recommended; this should be increased gradually until the desired systolic arterial pressure is attained. The usual dose is 25-200 micrograms / minute.

Children - No data are available on the use of glyceryl trinitrate in children.

4.3 Contraindications

Hypersensitivity to nitrates or any of the excipients.

Acute circulatory failure (shock, circulatory collapse)

Hypotensive shock,

Severe hypotension (systolic blood pressure below 90 mm Hg)

Arterial hypoxaemia,

Uncorrected hypovolaemia and angina caused by hypertrophic obstructive cardiomyopathy.

Cardiogenic shock, unless intra-aortic counterpulsation or positively inotropic drugs ensure an adequately high left-ventricular end-diastolic pressure

Severe anaemia

Toxic pulmonary oedema

Concomitant use of drugsused for the treatment of erectile dysfunction or pulmonary arterial hypertension (phosphodiesterase inhibitors, soluble guanylate cyclase stimulators) (section 4.5), can cause a considerable increase in the hypotensive effect and the resulting severe side effects (e.g. syncopes, paradoxical myocardial ischaemia). Therefore these drugs should not be used at the same time as Nitronal.

Cerebral haemorrhage and conditions associated with increased intracranial pressure (further elevation of the blood pressure has so far been observed only in association with high-dose IV administration of glyceryl trinitrate)

Marked bradycardia

4.4 Special warnings and precautions for use

Caution should be exercised in patients with severe liver or renal disease, hypothermia, hypothyroidism.

Nitronal® should not be given by bolus injection(see section 4.2).

Nitronal contains glucose monohydrate (49mg/ml). This should be considered if Nitronal is to be administered to patients with diabetes mellitus.

Glyceryl Trinitrate 1 mg/ml solution for infusion should be administered using polyethylene or polytetrafluorethylene tubings. Use of polyvinylchloride or polyurethane tubings may lead to a considerable loss of active substance due to adsorption.

Caution should be exercised when glyceryl trinitrate is administered to patients with:

- constrictive pericarditis and pericardial tamponade

- Low filling pressures arising from conditions including acute myocardial infarction, and left ventricular failure. A reduction of the systolic blood pressure below 90 mm Hg must be avoided in such situations.

- Cerebrovascular disease since symptoms may be triggered by hypotension

- aortic and/or mitral stenosis

- a tendency to orthostatic disturbances of circulatory regulation

In volume depleted patients, adequate volume replacement is required at the start of treatment.

The use of glyceryl trinitrate could theoretically compromise myocardial blood supply in patients with left ventricular hypertrophy associated with aortic stenosis because of the detrimental effects of tachycardia and decreased aortic diastolic pressure.

4.5 Interaction with other medicinal products and other forms of interaction

Glyceryl trinitrate may potentiate the action of other hypotensive drugs, and the hypotensive and anticholinergic effects of tricyclic anti-depressants.

N-acetylcysteine may potentiate the vasodilative effects of glyceryl trinitrate.

The hypotensive effects of glyceryl trinitrate solution for infusion are potentiated by concurrent administration of

- certain drugs used for the treatment of erectile dysfunction or pulmonary arterial hypertension (phosphodiesterase-5-inhibitor, soluble guanylate cyclase stimulator). A severe and possibly dangerous fall in blood pressure may occur. This can result in collapse, unconsciousness and may be fatal. Such use is therefore contra-indicated (section 4.3) If a patient treated with these drugs for erectile dysfunction or pulmonary arterial hypertension needs a rapidly effective nitrate, he/she should be closely monitored.

- other vasodilators, ß -blockers, calcium antagonists, neuroleptics, alcohol and sapropterin

If used concomitantly with dihydroergotamine, glyceryl trinitrate solution for infusion may lead to an increase in the DHE level and thus potentiate its hypertensive action.

In patients previously treated with organic nitrates, e.g. isosorbide dinitrate, isosorbide-5-mononitrate, a higher dose of glyceryl trinitrate may be necessary to achieve the desired haemodynamic effect.

4.6 Fertility, pregnancy and lactation


For glyceryl trinitrate no clinical data on exposed pregnancies are available.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development.


It is unknown if glyceryl trinitrate or its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue/abstain from breast-feeding or to discontinue/abstain from glyceryl trinitrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.


Animal studies did not indicate harmful effects with respect to fertility. However, the relevance of these animal findings to man is unknown.

4.7 Effects on ability to drive and use machines

Even when used as directed, this drug may affect the ability to drive or operate machinery.

This can occur in particular at the beginning of the treatment, with an increase of the dosage, when changing the medicinal product or when used in combination with alcohol.

4.8 Undesirable effects

Adverse reactions are listed below in descending order by frequency of occurrence.

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Very common

(≥ 1/10)


(≥ 1/100 to < 1/10)


(≥ 1/1,000 to < 1/100)


(≥ 1/10,000 to < 1/1,000)

Very rare

(< 1/10,000)

Not known

(cannot be estimated from the available data)

Blood and lymphatic system disorders

Very rare: Methaemoglobinaemia

Psychiatric disorder

Very rare: Restlessness

Nervous system disorders

Very common: Headache*,

Common: Dizziness, Drowsiness

Uncommon: Syncope

Very rare: Cerebral ischaemia

Cardiac disorders

Common: Tachycardia

Uncommon: Enhanced angina pectoris symptoms, Bradycardia, Cyanosis

Vascular disorders

Common: Orthostatic hypotension*

Uncommon: Facial flushing, Circulatory collapse

Gastrointestinal disorders

Uncommon: nausea, vomiting

Respiratory, thoracic and mediastinal disorders

Very rare: Impairment of respiration**

Skin and subcutaneous tissue disorders

Very rare: Exfoliative dermatitis, Drug rash

General disorders and administration site conditions

Common: Asthenia

Not known: drug tolerance***

Not known: Diaphoresis


Common: Blood pressure decreased*

*Particularly upon initiation of therapy and following an increase in dose.

**During the administration of Nitronal® , a transient hypoxaemia may occur due to relative redistribution of the blood flow in hypoventilated alveolar regions, which, in patients with coronary heart disease, may lead to ischaemia.

***The development of tolerance and the occurrence of cross tolerance to other nitro compounds have been described. In order to avoid attenuation or loss of effect, high continuous dosage should be avoided.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms of overdose

Signs and symptoms of overdose are generally similar to the described adverse reactions: e.g. drop in blood pressure with orthostatic regulatory disturbances, reflex tachycardia and headaches, weakness, dizziness, somnolence, flush, nausea, vomiting and diarrhoea may occur.

At high doses (more than 20 mg/kg body-weight) methaemoglobinemia, cyanosis, dyspnoea and tachypnoea must be anticipated owing to nitrite ions formed during the metabolism of glyceryl trinitrate.

At very high doses an increase in intracranial pressure with cerebral symptoms may occur.

At chronic overdosage increased methaemoglobin levels were measured of which the clinical relevance is controversial.

Treatment in the event of overdose

In the case of overdose, the patient's clinical status including vital signs and mental status should be assessed and supportive treatment of the cardiovascular and respiratory systems provided as clinically indicated or as recommended by the national poisons centre, where available.

In the event of mild hypotension, passive elevation of the patient's legs and/or lowering of the head may be effective.

If there is pronounced hypotension and/or shock a volume replacement should be performed; in exceptional cases, norepinephrine (noradrenaline) and/or dopamine can be infused as a cardiovascular therapy. Administration of epinephrine and related substances is contraindicated.

Arterial blood gas estimation should be performed and if there is acidosis or the patient is clinically cyanosed, then severe methaemoglobinaemia must be assumed. Oxygen therapy should be given with IV Methylene Blue over five min unless the patient is known to have Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Glyceryl trinitrate exerts a spasmolytic action on smooth muscle, particularly in the vascular system. The predominant effect is an increase in venous capacitance resulting in marked diminution of both the left ventricular filling pressure and volume (preload). There is also a reduction in afterload due to moderate dilation of the arteriolar resistance vessels. These haemodynamic changes lower the myocardial oxygen demand. By direct action and through the reduction of myocardial wall tension glyceryl trinitrate also lowers the resistance to flow in the coronary collateral channels and allows re-distribution of blood flow to ischaemic areas of the myocardium.

Administration of Nitronal® by intravenous infusion to patients with congestive heart failure results in a marked improvement in haemodynamics, reduction of elevated left ventricular filling pressure and systolic wall tension, and an increase in the depressed cardiac output. It reduces the imbalance that exists between myocardial oxygen demand and delivery, thereby diminishing myocardial ischaemia and controlling ischaemia-induced ventricular arrhythmias.

5.2 Pharmacokinetic properties

It is important that the dose of Nitronal® be titrated against the individual clinical response.

After intravenous administration, glyceryl trinitrate is widely distributed in the body with an estimated apparent volume of distribution of approximately 200 litres, and is rapidly metabolised to dinitrate and mononitrate with an estimated half life of 1 to 4 minutes, resulting in plasma levels of less than 1 microgram / ml.

5.3 Preclinical safety data

Tests with glyceryl trinitrate in cell cultures and in animal experiments showed no evidence of mutagenic or carcinogenic effects in the therapeutic dose range. Reproduction studies in animals were conducted with intravenous, intraperitoneal and dermal application. In studies on embryotoxicity and fertility no evidence of an influence on the embryo or evidence of fertility disorders were found in a dose range up to one which was toxic for the parent animals. In particular, there were no indications whatsoever pointing to any possible teratogenic properties. Doses above 1 mg/kg/day (i.p.) and 28 mg/kg/day (dermal) showed fetotoxic effects (reduced birthweights) after application during fetal development in pregnant rats. No data from investigations to determine the concentration of active ingredient in breast milk are on file.

6. Pharmaceutical particulars
6.1 List of excipients

Glucose Monohydrate

water for injections

Dilute hydrochloric acid (for pH adjustment)

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. When using the drug in combination with other solutions for infusion, it is necessary to follow the information of the manufacturer especially concerning (in)compatibilities, contraindications, undesirable effects and interaction with other medicinal products and other forms of interactions.

Glyceryl trinitrate is adsorbed onto administration systems composed of polyvinyl chloride or polyurethane, - see 6.6.

6.3 Shelf life

Ampoules: 3 years

Vial: 2 years

The diluted solution should be administered as soon as possible; it is stable for up to 24 hours in the recommended infusion system.

6.4 Special precautions for storage

Do not store above 25° C. Do not freeze. Store in the original container.

6.5 Nature and contents of container

Cartons of 10 ampoules or single vials.

Amber glass ampoule (containing 5 ml, 10 ml or 25 ml).

Clear glass vial (containing 50 ml).

Not all pack sizes may be marketed

6.6 Special precautions for disposal and other handling

As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate and discoloration as well as damage to the container (e.g. cracks) prior to administration.

Nitronal® need not be diluted before use but can be diluted with 5% Glucose Infusion, Sodium Chloride and Glucose Infusion, 0.9% Sodium Chloride Infusion or other protein-free infusion solution, if required.

The solution, whether or not diluted, should be infused slowly (see dosage section) and not given by bolus injection.

To ensure a constant infusion rate of glyceryl trinitrate it is recommended that Nitronal® be administered by means of a syringe pump or polyethylene infusion bag with a counter, or with a glass or rigid polyethylene syringe and polyethylene tubing. Systems made of polyvinyl chloride may absorb up to 50% of the glyceryl trinitrate from the solution, thus reducing the efficacy of the infusion. If the recommended type of system is unavailable, a 1:10 dilution of Nitronal® should be used and the infusion rate modified according to the haemodynamic response of the patient, until the required parameters are attained.

7. Marketing authorisation holder

G. Pohl-Boskamp GmbH & CO KG.

Kieler Strasse 11

25551 Hohenlockstedt


8. Marketing authorisation number(s)

PL 04719/0006

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Company Contact Details
Beaumont Pharma Ltd

Lashbrook Lodge, New Road, Shiplake, Henley-on-Thames, RG9 3LH, UK

Medical Information Direct Line

0330 1359 498

Customer Care direct line

+44 (0)7831 400 405

Stock Availability

+44 (0)7831 400 405


+44 (0)7831 400 405

Medical Information e-mail
Medical Information Fax

+44 (0)1908 533 370